It is known that IL-6 is elevated in patients with severe COVID-19 owing to an excessive immune response, which correlates with disease severity;[15] thus, the usefulness of tocilizumab as a therapeutic agent against COVID-19 has been investigated. This evidence concerns the gene IL6 and COVID-19.